Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Colorectal Cancer | Research

Impact of preoperative white blood cell count on outcomes in different stage colorectal cancer patients undergoing surgical resection: a single-institution retrospective cohort study

Authors: Bei Wang, Dandan Ling, Lihong Li, Jun Zhang, Jianghui Xu

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Purpose

To explore the association between preoperative WBC count and the long-term survival outcomes and clinical outcomes in different stage patients who underwent surgical resection for colorectal cancer (CRC).

Patients and methods

A cohort of 8121 Chinese patients who underwent surgical resection for CRC from January 1, 2008 to December 31, 2014 were enrolled as part of the retrospective cohort were retrospectively analyzed. Based on that the preoperative WBC optimal cut-off value was 7*109/L (7,000/µL), the high preoperative WBC group and the low preoperative WBC group was defined. Inverse probability of treatment weighting (IPTW) using the propensity score was used to reduce confounding. The impact of preoperative WBC count on overall survival (OS) and disease-free survival (DFS) was investigated using the Kaplan-Meier method and Univariate Cox proportional hazards models in different stage subgroup respectively.

Results

After IPTW, the clinical characters in the high preoperative WBC count group and the low preoperative WBC count group were balanced. Kaplan-Meier analysis showed that the 5-year OS rate were significantly lower in the high preoperative WBC count group overall, in stage II and IV. The 5-year DFS rate was significantly lower overall, in stage II and III in the high preoperative WBC count group. High preoperative WBC count was associated with poorer OS overall in stage II and stage IV.

Conclusions

This study suggests that preoperative WBC count is an independent risk factor for survival in patients undergoing colorectal surgery and may need to consider the stage of cancer when applied to predict long-term adverse outcome prognosis.
Literature
1.
Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol. 2019;16(12):713–32.CrossRefPubMed
2.
Brouwer NPM, Bos A, Lemmens V, et al. An overview of 25 years of incidence, treatment and outcome of colorectal cancer patients. Int J Cancer. 2018;143(11):2758–66.CrossRefPubMedPubMedCentral
3.
Wang B, Li L, Wang S, Zhou C, Sun Z, Weng M. 2022.
4.
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.CrossRefPubMed
5.
Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022;135(5):584–90.CrossRefPubMed
6.
Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–91.CrossRefPubMed
7.
Araghi M, Soerjomataram I, Jenkins M, et al. Global trends in colorectal cancer mortality: projections to the year 2035. Int J Cancer. 2019;144(12):2992–3000.CrossRefPubMed
8.
Park JH, McMillan DC. Outcome in colorectal cancer-tumour, stroma and so much more. Ann Oncol. 2018;29(3):534–5.CrossRefPubMed
9.
Wesselink E, van Baar H, van Zutphen M et al. Inflammation is a mediating factor in the association between lifestyle and fatigue in Colorectal Cancer patients. Cancers (Basel). 2020;12(12).
10.
Neufert C, Heichler C, Brabletz T, et al. Inducible mouse models of colon cancer for the analysis of sporadic and inflammation-driven tumor progression and lymph node metastasis. Nat Protoc. 2021;16(1):61–85.CrossRefPubMed
11.
Ma L, Gonzalez-Junca A, Zheng Y et al. Inflammation mediates the development of aggressive breast Cancer following Radiotherapy. Clin Cancer Res 2021.
12.
Godsland IF, North BV, Johnston DG. Simple indices of inflammation as predictors of death from cancer or cardiovascular disease in a prospective cohort after two decades of follow-up. QJM. 2011;104(5):387–94.CrossRefPubMed
13.
Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: neutral no more. Nat Rev Cancer. 2016;16(7):431–46.CrossRefPubMed
14.
Hu X, Li YQ, Li QG, Ma YL, Peng JJ, Cai SJ. Baseline peripheral blood leukocytosis is negatively correlated with T-Cell Infiltration Predicting worse outcome in colorectal cancers. Front Immunol. 2018;9:2354.CrossRefPubMedPubMedCentral
15.
Larsson AM, Nordström O, Johansson A, Rydén L, Leandersson K, Bergenfelz C. Peripheral blood mononuclear cell populations correlate with outcome in patients with metastatic breast Cancer. Cells 2022;11(10).
16.
Shaul ME, Fridlender ZG. Tumour-associated neutrophils in patients with cancer. Nat Rev Clin Oncol. 2019;16(10):601–20.CrossRefPubMed
17.
Hoskin PJ, Rojas AM, Peiris SN, Mullassery V, Chong IY. Pre-treatment haemoglobin and peripheral blood lymphocyte count as independent predictors of outcome in carcinoma of cervix. Clin Oncol (R Coll Radiol). 2014;26(4):179–84.CrossRefPubMed
18.
Mabuchi S, Matsumoto Y, Isohashi F, et al. Pretreatment leukocytosis is an indicator of poor prognosis in patients with cervical cancer. Gynecol Oncol. 2011;122(1):25–32.CrossRefPubMed
19.
Zhang H, Lv H, Weng M, et al. Preoperative leukocytosis is associated with increased tumor-infiltrating neutrophil extracellular traps and worse outcomes in esophageal cancer. Ann Transl Med. 2020;8(7):441.CrossRefPubMedPubMedCentral
20.
Gouw ZAR, Paul de Boer J, Navran A, van den Brekel MWM, Sonke JJ, Al-Mamgani A. Baseline peripheral blood leukocytosis: Biological marker predicts outcome in oropharyngeal cancer, regardless of HPV-status. Oral Oncol. 2018;78:200–6.CrossRefPubMed
21.
Martin D, Rödel F, Winkelmann R, Balermpas P, Rödel C, Fokas E. Peripheral leukocytosis is inversely correlated with Intratumoral CD8 + T-Cell infiltration and Associated with worse outcome after Chemoradiotherapy in Anal Cancer. Front Immunol. 2017;8:1225.CrossRefPubMedPubMedCentral
22.
Weng M, Zhao W, Yue Y, et al. High preoperative white blood cell count determines poor prognosis and is associated with an immunosuppressive microenvironment in colorectal cancer. Front Oncol. 2022;12:943423.CrossRefPubMedPubMedCentral
23.
Bruni D, Angell HK, Galon J. The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20(11):662–80.CrossRefPubMed
24.
Mathew G, Agha R, Albrecht J, et al. STROCSS 2021: strengthening the reporting of cohort, cross-sectional and case-control studies in surgery. Int J Surg. 2021;96:106165.CrossRefPubMed
25.
Rimini M, Franco P, De Bari B et al. The Prognostic Value of the New Combined Hemo-Eosinophil inflammation index (HEI Index): a Multicenter Analysis of Anal Cancer patients treated with Concurrent Chemo-Radiation. Cancers (Basel) 2021;13(4).
26.
Abu-Zaid A, Alomar O, Baradwan S, et al. Preoperative leukocytosis correlates with unfavorable pathological and survival outcomes in endometrial carcinoma: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2021;264:88–96.CrossRefPubMed
27.
Beetz O, Weigle CA, Cammann S, et al. Preoperative leukocytosis and the resection severity index are independent risk factors for survival in patients with intrahepatic cholangiocarcinoma. Langenbecks Arch Surg. 2020;405(7):977–88.CrossRefPubMedPubMedCentral
28.
Trujillo-Santos J, Di Micco P, Iannuzzo M, et al. Elevated white blood cell count and outcome in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost. 2008;100(5):905–11.CrossRefPubMed
29.
Moghadamyeghaneh Z, Hanna MH, Carmichael JC, Mills SD, Pigazzi A, Stamos MJ. Preoperative leukocytosis in Colorectal Cancer patients. J Am Coll Surg. 2015;221(1):207–14.CrossRefPubMed
30.
Curtis NJ, Primrose JN, Thomas GJ, Mirnezami AH, Ottensmeier CH. The adaptive immune response to colorectal cancer: from the laboratory to clinical practice. Eur J Surg Oncol. 2012;38(10):889–96.CrossRefPubMed
31.
Taussky D, Souliéres D, Azoulay L, et al. A combination of Testosterone and White Blood Cell Count as a predictive factor of overall survival in localized prostate Cancer. Target Oncol. 2017;12(5):695–701.CrossRefPubMed
32.
Schernberg A, Moureau-Zabotto L, Del Rivin E, et al. Leukocytosis and neutrophilia predict outcome in locally advanced esophageal cancer treated with definitive chemoradiation. Oncotarget. 2017;8(7):11579–88.CrossRefPubMedPubMedCentral
33.
Hou J, Karin M, Sun B. Targeting cancer-promoting inflammation - have anti-inflammatory therapies come of age? Nat Rev Clin Oncol 2021.
34.
Nilsson MP, Scherman J, Gunnlaugsson A, Leon O, Johnsson A, Nilsson ED. Treatment-related leukopenia in anal cancer patients associated with worse outcome: results of a retrospective cohort study. Acta Oncol. 2020;59(12):1508–11.CrossRefPubMed
35.
Kinoshita T, Goto T. Links between inflammation and postoperative Cancer recurrence. J Clin Med 2021;10(2).
36.
Tuomisto AE, Mäkinen MJ, Väyrynen JP. Systemic inflammation in colorectal cancer: underlying factors, effects, and prognostic significance. World J Gastroenterol. 2019;25(31):4383–404.CrossRefPubMedPubMedCentral
37.
Barna AJ, Herold Z, Acs M et al. High tumor-infiltrating lymphocyte count is Associated with distinct gene expression Profile and longer patient survival in Advanced Ovarian Cancer. Int J Mol Sci 2023;24(18).
38.
Li Y, Xu T, Wang X, Jia X, Ren M, Wang X. The prognostic utility of preoperative neutrophil-to-lymphocyte ratio (NLR) in patients with colorectal liver metastasis: a systematic review and meta-analysis. Cancer Cell Int. 2023;23(1):39.CrossRefPubMedPubMedCentral
39.
Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathol. 2014;232(2):199–209.CrossRefPubMed
40.
Kirilovsky A, Marliot F, El Sissy C, Haicheur N, Galon J, Pagès F. Rational bases for the use of the immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. Int Immunol. 2016;28(8):373–82.CrossRefPubMedPubMedCentral
41.
42.
43.
Pagès F, Mlecnik B, Marliot F, et al. International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391(10135):2128–39.CrossRefPubMed
Metadata
Title
Impact of preoperative white blood cell count on outcomes in different stage colorectal cancer patients undergoing surgical resection: a single-institution retrospective cohort study
Authors
Bei Wang
Dandan Ling
Lihong Li
Jun Zhang
Jianghui Xu
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-11983-7

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

Preoperative IL-8 levels as prognostic indicators of overall survival: an extended follow-up in a prospective cohort with colorectal liver metastases

Research

“How can a woman live without having a breast?”: challenges related to mastectomy in Ethiopia

Research

Neutrophil to lymphocyte ratio as an assessment tool to differentiate between uterine sarcoma and myoma: a systematic review and meta-analysis

Research

Translation and validation of a simplified Chinese version of the psychosocial assessment tool

Study Protocol

Habitat escalated adaptive therapy (HEAT): a phase 2 trial utilizing radiomic habitat-directed and genomic-adjusted radiation dose (GARD) optimization for high-grade soft tissue sarcoma

Research

Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits